Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Trend | Peers | Company |
|---|---|---|
| Is return on equity increasing? | No | Yes |
| Is net profit margin increasing? | Yes | Yes |
| Is asset turnover increasing? | Yes | Yes |
| Is equity multiplier increasing? | Yes | Yes |
| Competitors Used |
|---|
| Zevra Therapeutics, Inc. |
| Collegium Pharmaceutical, Inc. |
| Phathom Pharmaceuticals, Inc. |
| Aquestive Therapeutics, Inc. |
| ANI Pharmaceuticals, Inc. |
| Return on Equity Benchmarks | ||||||||
| Comparable Companies | ||||||||
| ZVRA | COLL | PHAT | AQST | ANIP | CPIX | |||
| Return On Equity | ||||||||
| Latest Twelve Months | -205% | 19% | 142% | 112% | -5% | -12% | ||
| Fiscal Year - 1 | -67% | 25% | 273% | 7% | 4% | -19% | ||
| Fiscal Year - 2 | -26% | -13% | NA | 54% | -15% | -14% | ||
| Fiscal Year - 3 | -207% | 37% | NA | 108% | -16% | -12% | ||
| Fiscal Year - 4 | 18% | 20% | NA | 204% | -11% | -13% | ||
| Fiscal Year - 5 | 35% | -25% | NA | -3347% | 3% | -17% | ||
| Average | -75% | 10% | 208% | -477% | -7% | -15% | ||
| Median | -47% | 19% | 208% | 81% | -8% | -14% | ||
| Benchmarks | Ticker | |||||||
| Zevra Therapeutics, Inc. | NasdaqGS:ZVRA | |||||||
| Collegium Pharmaceutical, Inc. | NasdaqGS:COLL | |||||||
| Phathom Pharmaceuticals, Inc. | NasdaqGS:PHAT | |||||||
| Aquestive Therapeutics, Inc. | NasdaqGM:AQST | |||||||
| ANI Pharmaceuticals, Inc. | NasdaqGM:ANIP | |||||||
| Financial Performance | ||||||||
| Comparable Companies | ||||||||
| (in millions) | ZVRA | COLL | PHAT | AQST | ANIP | CPIX | ||
| Latest Fiscal Year | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
| LTM Period | Mar-25 | Mar-25 | Mar-25 | Mar-25 | Mar-25 | Mar-25 | ||
| Revenues | ||||||||
| Latest Twelve Months | 41 | 664 | 82 | 54 | 674 | 41 | ||
| Fiscal Year | 24 | 631 | 55 | 58 | 614 | 38 | ||
| Fiscal Year - 1 | 27 | 567 | 1 | 51 | 487 | 40 | ||
| Fiscal Year - 2 | 10 | 464 | NA | 48 | 316 | 42 | ||
| Fiscal Year - 3 | 29 | 277 | NA | 51 | 216 | 36 | ||
| Fiscal Year - 4 | 13 | 310 | NA | 46 | 208 | 37 | ||
| Fiscal Year - 5 | 13 | 297 | NA | 53 | 207 | 34 | ||
| Net Income | ||||||||
| Latest Twelve Months | (92) | 44 | (346) | (54) | (22) | (3) | ||
| Fiscal Year | (106) | 69 | (334) | (44) | (20) | (6) | ||
| Fiscal Year - 1 | (46) | 48 | (202) | (8) | 15 | (6) | ||
| Fiscal Year - 2 | (27) | (25) | (198) | (54) | (50) | (6) | ||
| Fiscal Year - 3 | (63) | 72 | (144) | (71) | (43) | (6) | ||
| Fiscal Year - 4 | (13) | 27 | (129) | (56) | (23) | (7) | ||
| Fiscal Year - 5 | (25) | (23) | (255) | (66) | 6 | (9) | ||
| Total Assets | ||||||||
| Latest Fiscal Quarter Prior | 151 | 1,114 | 356 | 130 | 915 | 82 | ||
| Latest Fiscal Quarter | 173 | 1,631 | 294 | 102 | 1,292 | 70 | ||
| Fiscal Year | 178 | 1,664 | 378 | 101 | 1,284 | 76 | ||
| Fiscal Year - 1 | 172 | 1,143 | 414 | 57 | 904 | 82 | ||
| Fiscal Year - 2 | 115 | 1,174 | 165 | 57 | 760 | 93 | ||
| Fiscal Year - 3 | 133 | 692 | 189 | 62 | 772 | 84 | ||
| Fiscal Year - 4 | 11 | 644 | 295 | 63 | 461 | 96 | ||
| Fiscal Year - 5 | 11 | 306 | 257 | 78 | 457 | 105 | ||
| Fiscal Year - 6 | 27 | 291 | 1 | 87 | 431 | 113 | ||
| Common Equity | ||||||||
| Latest Fiscal Quarter Prior | 49 | 222 | (149) | (36) | 452 | 27 | ||
| Latest Fiscal Quarter | 41 | 234 | (338) | (61) | 419 | 29 | ||
| Fiscal Year | 40 | 229 | (254) | (60) | 404 | 23 | ||
| Fiscal Year - 1 | 62 | 195 | (73) | (106) | 433 | 30 | ||
| Fiscal Year - 2 | 75 | 195 | (75) | (119) | 314 | 36 | ||
| Fiscal Year - 3 | 127 | 203 | 72 | (82) | 334 | 43 | ||
| Fiscal Year - 4 | (66) | 186 | 194 | (48) | 196 | 47 | ||
| Fiscal Year - 5 | (74) | 87 | 228 | (6) | 213 | 51 | ||
| Fiscal Year - 6 | (67) | 92 | (1) | 10 | 197 | 56 | ||